TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25283139
Drug: B-vitamins supplementation
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamins supplementation (vitamin D3 1200 IU, folic acid 500 μg, vitamin B12 500 μg, vitamin B6 50 mg, calcium carbonate 456 mg)
Study: 20008251
Drug: DNA methyltransferase
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA methyltransferase inhibitors
Study: 16865032
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual delivered by school‐based mental health clinicians (Control)
Study: 9058688
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 800 microg two times a day
Study: 2951261
Drug: Doxazosin (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1, 2, 4, 8 or 16 mg)
Study: 2951261
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 or 100 mg)
Study: 27151999
Drug: Psychoanalytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic therapy (PA)
Study: 27151999
Drug: Psychodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic therapy (PD)
Study: 21040556
Drug: Regular care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular care with individual outpatient consultation with a rheumatologist (treatment as usual)
Study: 29220542
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg QW
Study: 11124745
Drug: 10% triacylglycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% triacylglycerol emulsion infusion
Study: 9643859
Drug: Zinc lozenges,
Normalized name: Zinc Lozenges, Vitamin C with Zinc oral lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc lozenges, 10 mg, orally dissolved, 5 times a day (grades 1-6) or 6 times a day (grades 7-12)
Study: 28494765
Drug: Zinc lozenges
Normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc lozenges
Study: 8163780
Drug: Medication requirements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication requirements
Study: 16817279
Drug: Jinsang Liyan
Normalized name: Lian Fang
DrugBank: Nelumbo nucifera flower (DB14333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinsang Liyan Wan (Pills for a Good Voice by Relieving Sore‐Throat)
Study: 14510744
Drug: Oral esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral esomeprazole (40 mg o.d.)
Study: 14510744
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole (40 mg o.d.)
Study: 1316307
Drug: Cryotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy plus subcutaneous interferon (IFN) alpha 2a
Study: 3927805
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of diazepam orally
Study: 26707354
Drug: Propranolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1 mg/kg)
Study: 22488557
Drug: Glucagon (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (0.5 mg) administered intravenously during endoscopy (GL group)
Study: 22488557
Drug: Scopolamine butylbromide
Normalized name: Scopolamine butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine butylbromide (10 mg) administered intravenously during endoscopy (SC group)
Study: 22488557
Drug: No medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medications used prior to PET (NO group)
Study: 19757017
Drug: 0.25% UC781
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% UC781 gel
Study: 21830124
Drug: Verapamil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil infusion
Study: 9639377
Drug: Other antiarrhythmic
Normalized name: Other antiarrhythmics, class I and III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiarrhythmic drugs (procainamide, propafenone, propranolol, dl-sotalol, amiodarone)
Study: 9639377
Drug: All antiarrhythmic
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antiarrhythmic drugs
Study: 7990854
Drug: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol)
Normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) at a mean dose of 37 +/- 10 mg intramuscularly
Study: 7990854
Drug: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol)
Normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) co-administered with a mildly dyskinetic dose of levodopa infused intravenously
Study: 7990854
Drug: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol)
Normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) at low doses (2.5 and 5 mg)
Study: 31958428
Drug: Adherent to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherent to bisphosphonate therapy
Study: 31958428
Drug: Underwent DXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Underwent DXA testing prior to bisphosphonate prescription and incident fracture
Study: 24283172
Drug: Estradiol hemihydrate
Normalized name: Estradiol hemihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol hemihydrate 2 mg
Study: 24283172
Drug: No menopausal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No menopausal therapy (Control)
Study: 12814333
Drug: Oral clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clodronate 1600 mg/day
Study: 15877555
Drug: Nonpharmacological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonpharmacological intervention (5 consecutive days and nights of efforts to decrease daytime in-bed time, 30 minutes or more of daily sunlight exposure, increased physical activity, structured bedtime routine, and efforts to decrease nighttime noise and light)
Study: 10328256
Drug: Vigabatrin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (50 to 60 mg/kg per day)
Study: 10328256
Drug: Carbamazepine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (15 to 20 mg/kg per day)
Study: 2022014
Drug: Aspirin 324
Normalized name: aspirin 324 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 324 mg daily
Study: 25496464
Drug: Tofacitinib 1
Normalized name: tofacitinib 11 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 1 mg BID
Study: 25496464
Drug: Tofacitinib 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 3 mg BID
Study: 17322494
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 60 microg/kg daily
Study: 17322494
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) (15, 30 microg/kg daily)
Study: 11245709
Drug: Baclofen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (20 mg three times daily)
Study: 9716583
Drug: G‐CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (5 microgram/kg/d) subcutaneously
Study: 26503137
Drug: Oral liquid
Normalized name: ACAI ORAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid nutrition supplement (ONS) intervention
Study: 19917874
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Hydrochlorothiazide and Atenolol)
Study: 12039398
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) therapy, 40-60 sessions of oxygen breathing at 2.5-bar increased pressure in a hyperbaric chamber
Study: 10607254
Drug: High-dose, short-duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose, short-duration interferon-alpha2b (10 million units for 14 weeks)
Study: 10607254
Drug: Standard interferon
Normalized name: INTERFERON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard interferon regimen (3 MU three times weekly for 6 months)
Study: 10607254
Drug: High-dose, short-duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose, short-duration interferon-alpha2b
Study: 8607618
Drug: CAF +
Normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAF + TAM therapy (Arm A)
Study: 8607618
Drug: CAF +
Normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAF + MPA therapy (Arm B)
Study: 2182234
Drug: Intravenous anistreplase
Normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anistreplase (APSAC)
Study: 6280836
Drug: No BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No BCG immunotherapy
Study: 30545701
Drug: Labetalol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (0.3 mg·kg‐1 i.v.)
Study: 25682576
Drug: Ruxolitinib (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (15 or 20 mg twice a day)
Study: 21791454
Drug: hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: hylan G-F 20 (Synvisc)
Study: 9415336
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg ondansetron suppository once a day
Study: 9415336
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg intravenous ondansetron on day 1 followed by 8 mg tablet twice daily on days 2 and 3 (i.v. + p.o. group)
Study: 8424510
Drug: Alkalinized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine (20 mL of 1.37% lidocaine plus 1 mL sodium bicarbonate per 10 mL 1.5% lidocaine)
Study: 8424510
Drug: Non-alkalinized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-alkalinized lidocaine (20 mL of 1.37% lidocaine with added 1:200,000 epinephrine)
Study: 3310622
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of testosterone enanthate
Study: 27281019
Drug: Pegylated interferon‐alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon‐alfa‐2a (Peg‐IFN‐α) therapy
Study: 27281019
Drug: Nucleos(t)ide analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleos(t)ide analog alone or in combination with Peg‐IFN‐α
Study: 12224570
Drug: Chloroquine combined
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine combined with primaquine (25 mg/kg in 3 doses over 48 hours + 30 mg primaquine daily for 28 days)
Study: 9833916
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion (250 microg/h after a 250‐microg bolus for 5 days)
Study: 7855216
Drug: Flunitrazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1 mg) administered daily for 8 days
Study: 7855216
Drug: Flunitrazepam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (single dose)
Study: 24379592
Drug: Somatostatin and
Normalized name: Somatostatin and analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin and dexamethasone treatment
Study: 24379592
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition and nasogastric (NG) tube feeding (Control)
Study: 21757237
Drug: Standardized stepwise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized stepwise treatment regimen (SSTR)
Study: 16883525
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium group (1000 mg element calcium and 400 units of vitamin D daily for 12 months)
Study: 16883525
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium group (300 mg element calcium and 300 units of vitamin D daily for 12 months)
Study: 27466236
Drug: High-dose ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ibuprofen (2400 mg/day for 4 or 12 weeks)
Study: 23819220
Drug: Routine EA
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine EA treatment
Study: 12798752
Drug: Hepatic artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic artery occlusion (HAO) followed by intraportal 5‐fluorouracil (5‐Fu) infusion (1000 mg/m(2) for 5 days every sixth week)
Study: 12798752
Drug: Intra-arterial 5‐Fu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial 5‐Fu infusion + Leucovorin (100 mg i.v. for 2 days every second week) (HAI)
Study: 3928215
Drug: tocainide hydrochloride
Normalized name: Tocainide Hydrochloride
DrugBank: Tocainide (DB01056)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tocainide hydrochloride (200-600 mg daily)
Study: 11736967
Drug: Patient-controlled postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled postoperative oral feeding (PC group)
Study: 11736967
Drug: Fixed regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed regimen postoperative oral feeding (FR group)
Study: 9237935
Drug: GLA supplementation
Normalized name: GLA
DrugBank: Gamolenic acid (DB13854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLA supplementation at doses of 3.0 g/d and 6.0 g/d
Study: 9237935
Drug: GLA supplementation
Normalized name: GLA
DrugBank: Gamolenic acid (DB13854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLA supplementation at doses of 3.0 g/d
Study: 2964992
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose HRP112 (25mg DMPA plus 5mg estradiol cypionate)
Study: 2964992
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose HRP112 (12.5mg DMPA plus 2.5mg estradiol cypionate)
Study: 2964992
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose DMPA (25mg)
Study: 2964992
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose DMPA (12.5mg)
Study: 2964992
Drug: Estrogen-progestogen combination
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-progestogen combination preparations
Study: 19245538
Drug: Poly-l-lactic acid
Normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-l-lactic acid (PLA) injections administered every 2 weeks from week 0 (immediate group)
Study: 19245538
Drug: Poly-l-lactic acid
Normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-l-lactic acid (PLA) injections administered every 2 weeks from week 24 (deferred group)
Study: 11501509
Drug: Calcitriol 3
Normalized name: CALCITRIOL 3MCG/GM OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 3 microg g(‐1) ointment applied twice daily
Study: 11501509
Drug: Calcitriol combined
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol combined with betamethasone valerate (each applied separately, once daily)
Study: 11501509
Drug: Calcitriol 3
Normalized name: CALCITRIOL 3MCG/GM OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 3 microg g(‐1) ointment
Study: 9532517
Drug: Irbesartan 75
Normalized name: irbesartan 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 75 mg once a day
Study: 9532517
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg once a day
Study: 9532517
Drug: Irbesartan 75
Normalized name: irbesartan 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 75 mg twice a day
Study: 8300487
Drug: Aerosolised nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolised nifedipine 5 mg
Study: 8300487
Drug: Aerosolised verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolised verapamil 5 mg
Study: 31870942
Drug: Cortisol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (1 mg intravenously)
Study: 30200398
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of dark chocolate containing 70% cocoa
Study: 30200398
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of milk chocolate
Study: 15979994
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg Triptorelin (GnRH agonist)
Study: 9688055
Drug: Moderately stressed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately stressed capsules
Study: 9688055
Drug: Unstressed capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unstressed capsules
Study: 3176071
Drug: Ethanol (95%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (95%, 0.84 ml/kg) as positive control
Study: 30184254
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% (2.5 ml)
Study: 30184254
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% (5.0 ml)
Study: 30184254
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% (10 ml)
Study: 30184254
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% (15 ml)
Study: 30184254
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% (20 ml)
Study: 26032281
Drug: Yohimbine (α2-adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (α2-adrenoceptor antagonist)
Study: 24385236
Drug: ETC-1002 80
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETC-1002 80 mg QD for 2 weeks followed by 120 mg QD for 2 weeks
Study: 18824288
Drug: Ferumoxytol (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol (IV injection of 17 mL over 17 seconds)
Study: 18824288
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (IV injection of 17 mL over 17 seconds)
Study: 12359651
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (100 micro g, twice daily)
Study: 1467074
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg i.m. 12-hourly for 2 days
Study: 6584028
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg prostaglandin E2 vaginal pessaries
Study: 29508715
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of montelukast for 2 weeks followed by 10 mg of montelukast for 2 weeks
Study: 29508715
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of prednisolone for 2 weeks followed by 10 mg of montelukast for 2 weeks
Study: 29508715
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of montelukast for 2 weeks
Study: 19514864
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg/hydrochlorothiazide 12.5 mg
Study: 23235355
Drug: Moxonidine 0.4
Normalized name: moxonidine 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.4 mg
Study: 17510755
Drug: Asmasal inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asmasal inhaler (micronized drug)
Study: 8996294
Drug: Titrated oral
Normalized name: magnesium citrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oral ramipril (n = 20)
Study: 8996294
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (control, n = 15)
Study: 8488685
Drug: Theospirex retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theospirex retard 300 mg (single evening dose)
Study: 8488685
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (400 mg, single evening dose)
Study: 8488685
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations (Theospirex retard and reference preparation)
Study: 19301059
Drug: Pantoprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (80 mg i.v. bolus followed by 8 mg/h for 1 h)
Study: 15578473
Drug: target-controlled propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: target-controlled propofol (1-8 microg/mL plasma target concentration)
Study: 11382369
Drug: Propionyl-L-carnitine (2g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (2g/day orally) for 6 months
Study: 24531357
Drug: Semitendinosus +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semitendinosus + gracilis (ST/G)
Study: 23725526
Drug: 7.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g/day of dietary fiber for 12 weeks
Study: 19692210
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg i.v. once daily
Study: 19692210
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g i.v. once daily plus Metronidazole 500 mg i.v. twice daily
Study: 15600227
Drug: Combined (Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (Medication + CBT for 10 weeks)
Study: 15600227
Drug: Overlapping (Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overlapping (Medication for 5 weeks, CBT introduced at week 4, medication withdrawal after 5 weeks)
Study: 15600227
Drug: Medication ->
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication -> CBT (Medication alone for 5 weeks, then CBT alone for 5 weeks)
Study: 8215749
Drug: Nizatidine, 150
Normalized name: Nizatidine, 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine, 150 mg twice daily